These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 10897121

  • 1. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G, Barragán E, Bolufer P, Chillón C, García-Sanz R, Gómez T, Brunet S, González M, Sanz MA.
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [Abstract] [Full Text] [Related]

  • 2. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW.
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K, AML Study Group.
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [Abstract] [Full Text] [Related]

  • 6. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
    Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E, Parziale A, Marmont F, Diverio D, Divona M, Lo Coco F, Saglio G.
    Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.
    J Clin Oncol; 2003 Dec 01; 21(23):4413-22. PubMed ID: 14645432
    [Abstract] [Full Text] [Related]

  • 8. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K, Mitterbauer G, Mitterbauer M, Knöbl P, Schwarzinger I, Greinix HT, Rabitsch W, Fonatsch C, Mannhalter C, Lechner K, Jaeger U.
    Leuk Lymphoma; 2001 Dec 01; 42(5):923-31. PubMed ID: 11697647
    [Abstract] [Full Text] [Related]

  • 9. [Detection of CBF beta-MYH11 fusion transcript and inv(16)(p13;q22) in acute myelomonocytic leukemia(M4) by RT-PCR and FISH].
    He K, Gu B, Cao Q.
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan 01; 19(1):23-6. PubMed ID: 10921098
    [Abstract] [Full Text] [Related]

  • 10. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
    Monma F, Nishii K, Shiga J, Sugahara H, Lorenzo F, Watanabe Y, Kawakami K, Hosokai N, Yamamori S, Katayama N, Shiku H.
    Leuk Res; 2007 Apr 01; 31(4):471-6. PubMed ID: 17052753
    [Abstract] [Full Text] [Related]

  • 11. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
    Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D, Ganser A, Heil G.
    Genes Chromosomes Cancer; 2001 Apr 01; 30(4):342-8. PubMed ID: 11241787
    [Abstract] [Full Text] [Related]

  • 12. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
    Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K.
    J Clin Oncol; 2010 Aug 10; 28(23):3724-9. PubMed ID: 20625124
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
    Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF, Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel.
    Leukemia; 2006 Jan 10; 20(1):87-94. PubMed ID: 16281071
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
    Gau JP, Young JH, Lin TH, Yang YS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar 10; 63(3):175-81. PubMed ID: 10746412
    [Abstract] [Full Text] [Related]

  • 15. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N, Willemse MJ, Szczepanski T, van der Velden VH, Langerak AW, Vandekerckhove P, van Dongen JJ.
    Leukemia; 2002 Mar 10; 16(3):368-75. PubMed ID: 11896540
    [Abstract] [Full Text] [Related]

  • 16. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
    Martinelli G, Ottaviani E, Testoni N, Montefusco V, Pastano R, Tura S.
    Haematologica; 2000 May 10; 85(5):552-5. PubMed ID: 10800179
    [No Abstract] [Full Text] [Related]

  • 17. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.
    Exp Hematol; 2009 Jun 10; 37(6):659-72. PubMed ID: 19463768
    [Abstract] [Full Text] [Related]

  • 18. Assessment of residual disease in acute leukemia by means of polymerase chain reaction.
    Ruiz-Argüelles GJ, Garcés-Eisele J, Reyes-Núñez V, Pérez-Romano B, Ruiz-Argüelles A, Ramírez-Cisneros FJ, López-Martínez B, López-Tapia JD, Rivadeneyra-Espinoza L.
    Rev Invest Clin; 2000 Jun 10; 52(2):118-24. PubMed ID: 10846434
    [Abstract] [Full Text] [Related]

  • 19. High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study.
    Mitterbauer M, Laczika K, Novak M, Mitterbauer G, Hilgarth B, Pirc-Danoewinata H, Schwarzinger I, Haas OA, Fonatsch C, Lechner K, Jaeger U.
    Am J Clin Pathol; 2000 Mar 10; 113(3):406-10. PubMed ID: 10705822
    [Abstract] [Full Text] [Related]

  • 20. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 10; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.